GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund Inc (NYSE:DCF) » Definitions » Cash Flow from Operations

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund Cash Flow from Operations : $1.17 Mil (TTM As of Feb. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BNY Mellon Alcentra Global Creditome 2024 Target Term Fund Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Feb. 2024, BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's Net Income From Continuing Operations was $12.29 Mil. Its Depreciation, Depletion and Amortization was $0.00 Mil. Its Change In Working Capital was $0.57 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $-13.14 Mil. In all, BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's Cash Flow from Operations for the six months ended in Feb. 2024 was $-0.28 Mil.


BNY Mellon Alcentra Global Creditome 2024 Target Term Fund Cash Flow from Operations Historical Data

The historical data trend for BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund Cash Flow from Operations Chart

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cash Flow from Operations
Get a 7-Day Free Trial 1.88 21.22 13.15 0.48 14.26

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund Semi-Annual Data
Feb19 Aug19 Feb20 Aug20 Feb21 Aug21 Feb22 Aug22 Feb23 Aug23 Feb24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -10.39 10.87 12.81 1.45 -0.28

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's Cash Flow from Operations for the fiscal year that ended in Aug. 2023 is calculated as:

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's Cash Flow from Operations for the quarter that ended in Feb. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Feb. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BNY Mellon Alcentra Global Creditome 2024 Target Term Fund  (NYSE:DCF) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's net income from continuing operations for the six months ended in Feb. 2024 was $12.29 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's depreciation, depletion and amortization for the six months ended in Feb. 2024 was $0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's change in working capital for the six months ended in Feb. 2024 was $0.57 Mil. It means BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's working capital increased by $0.57 Mil from Aug. 2023 to Feb. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's cash flow from deferred tax for the six months ended in Feb. 2024 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's cash from discontinued operating Activities for the six months ended in Feb. 2024 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's asset impairment charge for the six months ended in Feb. 2024 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's stock based compensation for the six months ended in Feb. 2024 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's cash flow from others for the six months ended in Feb. 2024 was $-13.14 Mil.


BNY Mellon Alcentra Global Creditome 2024 Target Term Fund Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of BNY Mellon Alcentra Global Creditome 2024 Target Term Fund's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


BNY Mellon Alcentra Global Creditome 2024 Target Term Fund Business Description

Traded in Other Exchanges
N/A
Address
c/o BNY Mellon Investment Adviser, Inc., 240 Greenwich Street, New York, NY, USA, 10286
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund Inc is a diversified closed-end management investment company. Its investment objectives are to seek high current income and to return at least the Fund's original NAV to holders of record of common shares on or about the termination date.
Executives
Bushra Mannan other: Director of BNYMIA (1) C/O BNY MELLON INVESTMENT ADVISER, INC., 240 GREENWICH STREET, NEW YORK NY 10286
Irene Papadoulis other: Director of BNYMIA (1) C/O BNY MELLON INVESTMENT ADVISER, INC., 240 GREENWICH STREET, NEW YORK NY 10286
Ping Jiang other: Dir. of Invest. Oversight (1) C/O BNY MELLON INVESTMENT ADVISER, INC., 240 GREENWICH STREET, NEW YORK NY 10286
Bradley J Skapyak officer: President 200 PARK AVENUE, NEW YORK NY 10166
Joseph Martella officer: VP C/O BNY MELLON INVESTMENT ADVISER, INC., 240 GREENWICH STREET, NEW YORK NY 10288
Daniel Goldstein officer: VP 240 GREENWICH STREET, NEW YORK NY 10286
Robert J. Pomeroy officer: VP; Investment Adviser C/O BNY MELLON INVESTMENT ADVISER, INC., 240 GREENWICH STREET, NEW YORK NY 10286
Vinay Patel other: Head of Finance of Sub-Adviser 200 PARK AVE, NEW YORK CITY NY 10166
Alcentra Ny, Llc other: Sub-Adviser 200 PARK AVENUE, 7TH FLOOR, NEW YORK NY 10166
Brandon Chao other: Portfolio Mgr of Sub-Adviser 200 PARK AVENUE, NEW YORK CITY NY 10166
Laurence Raven other: Portfolio Mgr of Sub-Adviser 200 PARK AVENUE, NEW YORK CITY NY 10166
Ross Curran other: Portfolio Mgr of Sub-Adviser 200 PARK AVENUE, NEW YORK CITY NY 10166
Cathy Bevan other: Portfolio Mgr of Sub-Adviser 200 PARK AVENUE, NEW YORK CITY NY 10166
Daire Wheeler other: Portfolio Mgr of Sub-Adviser 200 PARK AVENUE, NEW YORK CITY NY 10166
Eric Larsson other: Portfolio Mgr of Sub-Adviser C/O ALCENTRA NY LLC, 200 PARK AVENUE, NEW YORK CITY NY 10166